Xconomy | Boston - Business + Technology in the Exponential Economy

Quanterix Developing Instrument to Detect Cancer at its Earliest, Most Curable Stages
How to Build a Billion-Dollar Company (And Keep An Academic Day Job), According to David Walt
Seventh Sense Biosystems Developing Tech Akin to Check-Engine Light for the Body
Federal Judge Rules in Biogen Idec’s Favor, Sepracor Agrees to $2.8B Buyout, FDA Panel Endorses Gloucester Pharma Drug, & More Boston-Area Life Sciences News
Quanterix Taps New CEO

Quanterix Collects $15 Million in Series A Venture Round

Quanterix, a privately held developer of medical diagnostics technology in Cambridge, MA, has raised $15 million in a Series A financing, according to VentureWire. Arch Venture Partners, Bain Capital, and Flagship Ventures participated in the financing. Tufts University researcher David Walt, a founder of San Diego-based Illumina (NASDAQ: ILMN) is a co-founder of Quanterix. The company’s technology is used to identify single molecules in human blood, which escape detection from standard Elisa diagnostic tests, according to the company’s web site.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: